Decreased muscle mass in type-2 diabetes. A hidden comorbidity to consider

被引:7
|
作者
de Luis Roman, Daniel [1 ]
Garrachon Vallo, Fernando [2 ]
Carretero Gomez, Juana [3 ]
Jose Lopez Gomez, Juan [1 ]
Jose Tarazona Santabalbina, Francisco [4 ]
Guzman Rolo, German [5 ]
Manuel Garcia Almeida, Jose [6 ]
Sanz Paris, Alejandro [7 ]
机构
[1] Hosp Clin Univ Valladolid, Serv Endocrinol & Nutr, Valladolid, Spain
[2] Hosp Univ Virgen Macarena, Serv Med Interna, Seville, Spain
[3] Hosp Univ Badajoz, Serv Med Interna, Badajoz, Spain
[4] Hosp Univ Ribera Alzira, Serv Geriatr, Valencia, Spain
[5] Labs Abbot, Dept Med, Madrid, Spain
[6] Hosp Clin Virgen de la Victoria, UGC Endocrinol & Nutr, Malaga, Spain
[7] Hosp Univ Miguel Servet, Serv Endocrinol, Zaragoza, Spain
关键词
Muscle mass; Type-2; diabetes; Malnutrition; Sarcopenia; HMB; STRENGTH; ASSOCIATION; RESISTANCE; SARCOPENIA; ADULTS;
D O I
10.20960/nh.04468
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objectives: an expert report is presented on the situation of loss of muscle mass in people with type 2 diabetes mellitus (T2DM), with a proposal of what the clinical approach to this comorbidity should be, based on the evidence from the literature and clinical experience. Method: a qualitative expert opinion study was carried out using the nominal approach. A literature search on diabetes and muscle was made and submitted to a multidisciplinary group of 7 experts who through a face-to-face meeting discussed different aspects of the role of muscle mass in T2DM.Results: muscle mass must be taken into account in the clinical context of patients with T2DM. It has an enormous impact on patient function and quality of life, and is as important as adequate metabolic control of T2DM.Conclusion: in addition to drug therapy and diet adjustments, aerobic and strength activities are essential for maintaining muscle mass and function in diabetic patients. In concrete situations, artificial oral supplementation specific for muscle care could improve the situation of mal-nutrition and low muscle mass. Measures such as the walking speed test, chair test, or the SARC-F questionnaire, together with the Barthel index, constitute a first step to diagnose relevant impairment requiring intervention in patients with T2DM. This document seeks to answer some questions about the importance, assessment, and control of muscle mass in T2DM.
引用
收藏
页码:59 / 66
页数:8
相关论文
共 50 条
  • [41] HYPOGLYCEMIA IN TYPE-2 DIABETES
    BIELEFELDT, K
    MEDIZINISCHE KLINIK, 1990, 85 (03) : 117 - 120
  • [42] MORTALITY IN TYPE-2 DIABETES
    REUNANEN, A
    ANNALS OF CLINICAL RESEARCH, 1983, 15 : 26 - 28
  • [43] Obesity as a Common Type-2 Diabetes Comorbidity: Eating Behaviors and Other Determinants in Jakarta, Indonesia
    Fajarini, Isna Aulia
    Sartika, Ratu Ayu Dewi
    KESMAS-NATIONAL PUBLIC HEALTH JOURNAL, 2019, 13 (04): : 157 - 163
  • [44] THE GENETICS OF TYPE-2 DIABETES
    KNOWLER, WC
    DIABETES 1988, 1989, 800 : 489 - 492
  • [45] WINE AND TYPE-2 DIABETES
    GIN, H
    DIABETIC MEDICINE, 1994, 11 (08) : 811 - 811
  • [46] DECREASED INSULIN SENSITIVITY IN OFFSPRING WHOSE PARENTS BOTH HAVE TYPE-2 DIABETES
    RAMACHANDRAN, A
    SNEHALATHA, C
    MOHAN, V
    BHATTACHARYYA, PK
    VISWANATHAN, M
    DIABETIC MEDICINE, 1990, 7 (04) : 331 - 334
  • [47] Effects of troglitazone and metformin on glucose metabolism, plasma leptin and E-selectin in type-2 diabetes.
    Wagner, OF
    Kautzky-Willer, A
    Ludvik, B
    Waldhäusl, W
    Pacini, G
    Prager, R
    DIABETOLOGIA, 1999, 42 : A226 - A226
  • [48] NEIGHBORHOOD DEPRIVATION AND CHANGE IN BODY MASS INDEX AMONG ADULTS WITH TYPE 2 DIABETES.
    Stoddard, P.
    Laraia, B.
    Warton, M.
    Adler, N.
    Karter, A.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 : S147 - S147
  • [49] Decreased α Melanocyte Stimulating Hormone (αMSH) Expression in the Hypothalamic Infundibular Nucleus of Subjects with Type 2 Diabetes.
    Alkemade, A.
    Harakalova, M.
    Swaab, D. F.
    Fliers, E.
    Kalsbeek, A.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [50] Mechanism of action of thiazozidinediones in type 2 diabetes.
    Levin, K
    Beck-Nielsen, H
    INSULIN RESISTANCE, METABOLIC DISEASES AND DIABETIC COMPLICATIONS, 1999, 1177 : 243 - 251